Suppr超能文献

[β受体阻滞剂在现代动脉高血压治疗中起作用吗?]

[Do beta-blockers have a role in the modern treatment of arterial hypertension?].

作者信息

Horký K

机构信息

II. interní klinika 1. LF UK a VFN, Praha.

出版信息

Vnitr Lek. 1996 Jun;42(6):420-5.

PMID:8928415
Abstract

The submitted review draws attention to advantages and pitfalls of the use of betablockers in the treatment of arterial hypertension. Despite certain metabolically adverse effects which are reduced to a minimum in small doses and more recent betablockers, the latter are along with diuretics the only antihypertensive agents where unequivocally the the long-term favourable effect on the general and cardiovascular mortality was proved. In other hypertensive agents results are expected after completion of multicentric studies which are underway. Beta-blockers, as monotherapy or combined with other drugs, are the drug of choice in the treatment of essential hypertension in young hypertonic patients with hyperkinetic circulation, a tendency for tachycardia, in hypertonic patients with ischaemic heart disease after myocardial infarction or with angina pectoris. In these subjects they quite obviously reduce the general as well as cardiovascular mortality, sudden death and myocardial re-infarction. Betablockers are effective also in elderly hypertonic patients where preparations with ISA or beta 1-selective preparations are more useful. With a certain amount of care similar types of beta-blockers or beta-blockers with a dual effect can be used in hypertension associated with diabetes mellitus, hyperlipoproteinaemia or ischaemia of the lower extremities. Beta-blockers are irreplaceable among antihypertensives of first choice and are experiencing their revival being effective, safe, cheap and well tolerated antihypertensive drugs. Their other properties such as the degree of selectivity, the presence of internal sympathetic activity, combined dual effect, lipophilic or hydrophilic character, enable us to indicate different preparations "tailored" with regard to the severity of hypertension, organ complications and associated diseases.

摘要

所提交的综述提请人们关注使用β受体阻滞剂治疗动脉高血压的优点和缺陷。尽管存在某些代谢方面的不良反应,但在小剂量使用以及使用最新的β受体阻滞剂时,这些不良反应已降至最低。β受体阻滞剂与利尿剂一起,是唯一已明确证明对总体死亡率和心血管死亡率具有长期有利影响的抗高血压药物。对于其他抗高血压药物,在正在进行的多中心研究完成后有望得出结果。β受体阻滞剂作为单一疗法或与其他药物联合使用,是治疗原发性高血压的首选药物,适用于年轻的高血压患者,这些患者具有高动力循环、心动过速倾向,以及心肌梗死后患有缺血性心脏病或心绞痛的高血压患者。在这些患者中,β受体阻滞剂显然能降低总体死亡率以及心血管死亡率、猝死率和心肌再梗死率。β受体阻滞剂对老年高血压患者也有效,其中具有内在拟交感活性(ISA)的制剂或β1选择性制剂更为有用。在一定程度的谨慎使用下,类似类型的β受体阻滞剂或具有双重作用的β受体阻滞剂可用于与糖尿病、高脂蛋白血症或下肢缺血相关的高血压。在首选抗高血压药物中,β受体阻滞剂是不可替代的,并且正经历复兴,它们是有效、安全、廉价且耐受性良好的抗高血压药物。它们的其他特性,如选择性程度、内在交感活性的存在、联合双重作用、亲脂性或亲水性特征,使我们能够根据高血压的严重程度、器官并发症和相关疾病“量身定制”不同的制剂。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验